Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
暂无分享,去创建一个
X. Montalban | M. Tintoré | L. Ramió-Torrentá | M. Comabella | J. Masjuán | A. Saiz | S. Llufriu | J. Álvarez-cermeño | B. Casanova | N. Villarrubia | J. Martínez-Rodríguez | L. Villar | A. Quiroga-Varela | S. Eichau | F. Pérez-Miralles | R. Álvarez-Lafuente | L. Brieva | S. Sainz de la Maza | M. Domínguez-Mozo | J. M. Cabrera-Maqueda | D. Lourido | L. Costa-Frossard | E. Monreal | J. I. Fernández-Velasco | M. García‐Sánchez | M. Espiño | J. L. Chico-García | Fernando Rodríguez-Jorge
[1] K. Blennow,et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years , 2022, Brain communications.
[2] F. X. Aymerich,et al. Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.
[3] D. Conen,et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study , 2022, The Lancet Neurology.
[4] V. Fleischer,et al. NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study , 2021, EBioMedicine.
[5] M. Freedman,et al. Serum neurofilament light in MS: The first true blood-based biomarker? , 2021, Multiple sclerosis.
[6] S. Fereshtehnejad,et al. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis , 2020, Scientific Reports.
[7] L. Kappos,et al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis , 2020, Neurology.
[8] M. Trojano,et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study , 2020, The Lancet Neurology.
[9] R. Henry,et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. , 2019, JAMA neurology.
[10] L. Kappos,et al. Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis , 2018, Annals of clinical and translational neurology.
[11] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[12] K. Blennow,et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.
[13] Ludwig Kappos,et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.
[14] Gavin Giovannoni,et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS , 2017, Neurology.
[15] OUP accepted manuscript , 2022, Brain.